Cancer of Unknown Primary: Challenges and Progress in Clinical Management
Open Access
Abstract
Distant metastases are the main cause of cancer-related deaths in patients with advanced tumors. A standard diagnostic workup usually contains the identification of the tissue-of-origin of metastatic tumors, although under certain circumstances, it remains elusive. This disease setting is defined as cancer of unknown primary (CUP). Accounting for approximately 3–5% of all cancer diagnoses, CUPs are characterized by an aggressive clinical behavior and represent a real therapeutic challenge. The lack of determination of a tissue of origin precludes CUP patients from specific evidence-based therapeutic options or access to clinical trial, which significantly impacts their life expectancy. In the era of precision medicine, it is essential to characterize CUP molecular features, including the expression profile of non-coding RNAs, to improve our understanding of CUP biology and identify novel therapeutic strategies. This review article sheds light on this enigmatic disease by summarizing the current knowledge on CUPs focusing on recent discoveries and emerging diagnostic strategies.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (IG2016 ID:18464)
- Austrian Science Fund (T1112-B)
This publication has 212 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primaryMolecular Cancer, 2013
- A Microarray-Based Gene Expression Analysis to Identify Diagnostic Biomarkers for Unknown Primary CancerPLOS ONE, 2013
- Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: Results of the randomised GEFCAPI 02 trialEuropean Journal of Cancer, 2012
- Carcinomas of an unknown primary origin—diagnosis and treatmentNature Reviews Clinical Oncology, 2011
- Validation and Reproducibility of a Microarray-Based Gene Expression Test for Tumor Identification in Formalin-Fixed, Paraffin-Embedded SpecimensThe Journal of Molecular Diagnostics, 2011
- miRNAs in human cancerThe Journal of Pathology, 2010
- Paclitaxel and carboplatin vs gemcitabine and vinorelbine in patients with adeno- or undifferentiated carcinoma of unknown primary: a randomised prospective phase II trialBritish Journal of Cancer, 2008
- Gene expression profiling may improve diagnosis in patients with carcinoma of unknown primaryBritish Journal of Cancer, 2008
- MicroRNA expression profiles classify human cancersNature, 2005